Atosiban, an oxytocin-receptor antagonist marketed in China in 2006, offers maintenance treatment to manage preterm labor risks after initial tocolysis. Clinical trials show it delays delivery better than placebo in some cases and has fewer side effects than beta-2 agonists. Studies highlight its…
Preterm labor stands as a leading cause of neonatal issues and mortality around the world. Current treatments focus on tocolysis to delay birth, but agents like sympathomimetics only postpone delivery by up to 48 hours during acute episodes. Patients often face repeated preterm labor, hospital stays, repeat intravenous treatments, and early births, where atosiban steps in as a maintenance option.
Marketed in China in 2006, atosiban acts as an oxytocin-receptor antagonist. It helps prevent these ongoing complications after initial therapy.
Atosiban binds competitively to oxytocin receptors located in the uterine decidual membrane and myometrium. This action blocks the rise in oxytocin receptor numbers, which in turn diminishes oxytocin's influence.
By lowering available receptors, atosiban reduces uterine contractions effectively. Researchers note this mechanism supports its use in maintenance therapy.
For peptide researchers, tools like the Peptide Glossary /tools/peptide-glossary provide definitions of terms such as oxytocin antagonists.
A multicenter, double-blind study by Romero involved 246 women in the atosiban group and 255 in the placebo control. Results showed higher rates of delaying delivery beyond 48 hours 67% versus 56% and 7 days 62% versus 49% with atosiban.
Shim et al. found atosiban outperformed litojun in efficacy and safety, with 59.7% versus 47.4% inhibition of uterine contractions compared to beta-2 receptor agonists.
However, atosiban caused far fewer adverse effects, particularly cardiovascular ones 8.3% versus 81.2% . Fewer participants stopped treatment due to side effects 1.1% versus 15.4% .
In a prospective cohort by De et al., 1920 pregnant women from 28 hospitals in the Netherlands or Belgium participated. Atosiban demonstrated strong maternal and fetal safety, with only one of 575 women experiencing nausea 0.2% incidence .
Peptide Atlas offers Free peptide tools /tools such as the Interaction Checker /tools/peptide-interaction-checker for assessing compound safety in research.
Atosiban provides a viable maintenance therapy option for preterm labor, excelling in safety over alternatives like beta-2 agonists. Trials confirm its ability to extend pregnancy intervals in some settings while minimizing side effects. Researchers can explore dosing with Peptide Atlas' Dosage & Cycle Planner /tools/peptide-dosage-planner and browse compounds in our catalog /catalog .
Peptides referenced: Oxytocin.
Related reading: Aviptadil Acetate's Potential in Pulmonary Arterial Hypertension, Aclerastide: Effective Therapy for Diabetic Foot Ulcers, TB4 Peptide: Key Functions and Research Insights, Peptide Atlas Research Team: Expertise and Standards.